Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 4/20 | 0.57 |
| ▸ | MMP1 | P03956 | 3/20 | 0.57 |
| ▸ | MMP2 | P08253 | 3/20 | 0.57 |
| ▸ | MMP9 | P14780 | 3/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | CDK9 | P50750 | 1/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4147796 | 0.83 | MMP1 (0.63) | TGM2CYP1A2NPSR1NAPRTHSD17B10 | |
| SCHEMBL4147799 | 0.83 | MMP1 (0.63) | TGM2CYP1A2NPSR1NAPRTHSD17B10 | |
| SCHEMBL19142994 | 0.83 | MMP1 (0.63) | TGM2CYP1A2NPSR1NAPRTHSD17B10 | |
| SCHEMBL6302448 | 0.81 | MMP1 (0.73) | TGM2CYP1A2NPSR1MAOBMMP1 | |
| SCHEMBL6302452 | 0.81 | MMP1 (0.73) | TGM2CYP1A2NPSR1MAOBMMP1 | |
| SCHEMBL9840923 | 0.81 | MMP1 (0.73) | TGM2CYP1A2NPSR1MAOBMMP1 | |
| SCHEMBL725250 | 0.79 | TGM2 (0.65) | TGM2CYP1A2NPSR1NAPRTHSD17B10 | |
| SCHEMBL2900749 | 0.79 | TGM2 (0.65) | TGM2CYP1A2NPSR1NAPRTHSD17B10 | |
| SCHEMBL1343362 | 0.78 | MDM2 (0.59) | CYP1A2SMN1; SMN2EPHX1NPC1RAB9A | |
| SCHEMBL7679084 | 0.78 | SMN1; SMN2 (0.67) | TGM2CYP1A2NPSR1NAPRTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009003911-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2009-01-08 | — | — | WO | claimed |
| EP-1398027-B1 | Use of matrix metalloproteinase inhibitors for treating or preventing glomerulopathy | SHIONOGI & CO (JP) | 2007-01-10 | — | — | EP | claimed |
| EP-1706147-A2 | COMBINATION THERAPY WITH 5-HT sb 1A /sb AND 5-HT sb 1B /sb RECEPTOR ANTAGONISTS | Recordati Ireland Limited (IE) | 2006-10-04 | — | — | EP | claimed |
| EP-1029541-B1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR GLOMERULOPATHY | SHIONOGI & CO (JP) | 2006-03-22 | — | — | EP | claimed |
| WO-2005070460-A2 | COMBINATION THERAPY WITH 5-HT1A AND 5-HT1B RECEPTOR ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2005-08-04 | — | — | WO | claimed |
| US-6737424-B2 | THERAPY FOR NERVOUS SYSTEM DISORDERS | ZENECA LTD. (GB) | 2004-05-18 | — | — | US | claimed |
| EP-1398027-A1 | Use of matrix metalloproteinase inhibitors for treating or preventing glomerulopathy | SHIONOGI & CO., LTD. (JP) | 2004-03-17 | — | — | EP | claimed |
| US-20030078434-A1 | Composition for treating or preventing glomerulopathy | SHIONOGI & CO., LTD. | 2003-04-24 | — | — | US | claimed |
| US-6423729-B1 | KIDNEY DISORDERS | SHIONOGI & CO., LTD. (JP) | 2002-07-23 | — | — | US | claimed |
| EP-1029541-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR GLOMERULOPATHY | SHIONOGI & CO., LTD. (JP) | 2000-08-23 | — | — | EP | claimed |
| US-4178383-A | Fungicidally active oxime-ethers of isonitrosocyanoacetamides | BAYER AKTIENGESELLSCHAFT (DE) | 1979-12-11 | — | — | US | claimed |
| CN-116507606-A | TES-based cationic lipids | 翻译生物公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116457027-A | Piperazine-based cationic lipids | 翻译生物公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20160050930-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | SYNGENTA LIMITED (UK) | 2016-02-25 | — | — | US | disclosed |
| EP-2978316-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | Syngenta Participations AG (CH) | 2016-02-03 | — | — | EP | disclosed |
| EP-0476760-A2 | 4-substituted isoxazole herbicides | EASTMAN KODAK COMPANY (US) | 1992-03-25 | — | — | EP | disclosed |
| CN-1030237-A | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 1989-01-11 | — | — | CN | disclosed |
| EP-0287951-A2 | 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-10-26 | — | — | EP | disclosed |
| US-4472300-A | ANTIMICROBIAL | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-09-18 | — | — | US | disclosed |
| US-4207234-A | 4-Unsubstituted azetidinone derivatives and process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078434-A1 | Composition for treating or preventing glomerulopathy | REN, TTR, ATP6V1B1 | TGM2 563/4885CYP1A2 2770/4885NPSR1 4294/4885 |
| US-20160050930-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | DDT, CRY1, NISCH | TGM2 3722/4885CYP1A2 167/4885NPSR1 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.